8
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Long-term prognosis in lupus nephritis: relation to the renal biopsy data, therapy, and grade of remission

, , , , , & show all
Pages 135-145 | Received 12 Mar 1998, Accepted 28 Oct 1998, Published online: 02 Jan 2014
 

Abstract

The relation between long term-prognosis and renal biopsy data or therapy were evaluated, and their contribution to remission was also considered. In total, 112 patients with new lupus nephritis who underwent renal biopsy and without other severe organ involvements were selected. These patients were divided into subgroups according to their renal biopsy data, and their clinical data were accumulated. Patients with World Health Organization (WHO) classification types III and IV had poor outcomes. Patients with mild lesions (WHO types I and II) had good outcomes when treated with low-dose steroid, while patients with severe lesions (WHO types III and IV) had better outcomes following medication with immunosuppressive agents. In particular, patients who received intravenous cyclophosphamide (IVCY) showed the best outcomes. Patients with WHO type III or IV classification without remission had poor outcomes, while those with complete remission had better outcomes. We conclude that renal biopsy data and course of therapy showed some relation in longterm prognosis, and the grade of remission was also related.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.